GenomicsNature MedicinePeer-reviewed
Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinsons disease
Nicola Whiffin, Irina M. Armean, Aaron Kleinman…·Matthew B. Harms
The paper analyzes loss-of-function variants in LRRK2 across large genomic datasets to assess the safety of partial LRRK2 inhibition as a Parkinson's disease therapy.
126 citationstop 1%